Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review

Open Access

Peer-reviewed

Research Article

George W. Rutherford ,

* E-mail: george.rutherford@ucsf.edu

Affiliation Global Health Sciences, University of California, San Francisco, San Francisco, California, United States of America
⨯
Hacsi Horvath

Affiliation Global Health Sciences, University of California, San Francisco, San Francisco, California, United States of America
⨯

Reader Comments (0)

Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.
Database searching
Is the Subject Area "Database searching" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Metaanalysis
Is the Subject Area "Metaanalysis" applicable to this article?

Thanks for your feedback.
Systematic reviews
Is the Subject Area "Systematic reviews" applicable to this article?

Thanks for your feedback.
Antiretroviral therapy
Is the Subject Area "Antiretroviral therapy" applicable to this article?

Thanks for your feedback.
Reverse transcriptase inhibitors
Is the Subject Area "Reverse transcriptase inhibitors" applicable to this article?

Thanks for your feedback.
Nucleosides
Is the Subject Area "Nucleosides" applicable to this article?

Thanks for your feedback.